Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016
Following successful public offering, Company well positioned to deliver key data points for glesatinib, sitravatinib and immuno-oncology combinations in 2017
View HTML
Toggle Summary Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference View HTML
Toggle Summary Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering of Common Stock View HTML
Toggle Summary Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs
Glesatinib demonstrates improved tolerability with new spray dried dispersion formulation;<br>Promising clinical activity observed in NSCLC patients with MET mutations;<br>Early clinical responses indicate sitravatinib an effective inhibitor of RET in NSCLC
View HTML
Toggle Summary Mirati Therapeutics Reports Financial Results And Provides Business Update For The Third Quarter 2016 View HTML
Toggle Summary Mirati Therapeutics Appoints Chris LeMasters To Role Of Executive Vice President And Chief Business Officer View HTML
Toggle Summary Mirati Therapeutics Announces Appointment Of Dr. Bruce L.A. Carter To Board Of Directors View HTML
Toggle Summary Mirati Therapeutics Reports Financial Results And Provides Business Update For The Second Quarter 2016 View HTML